The 11th edition of the Japanese Classification of Esophageal Cancer (EC) was published in 2017. Some correction was made in the depth of tumor invasion to be consistent with the TNM classification by the Union for International Cancer Control (UICC). With regard to surgery, short-term safety and long-term effectiveness under thoracotomy/video-assisted thoracoscopic surgery are expected to be proven by the Japan Clinical Oncology Group (JCOG)1409 study. Results of nutritional management and countermeasures for adverse events not only during the perioperative period but also during EC chemotherapy were reported. From now on, the pursuit of low invasiveness and radicality is desired. Esophageal surgery is also expected to be safe at all institutions. To determine the optimal modality of preoperative treatment and a novel chemo(radio)therapy regimen for patients with distant metastasis, the results of the ongoing JCOG1109 and 0807 studies are being 
singly or in combination with 5-fluorouracil (FU), vindesine, mitomycin, docetaxel, paclitaxel, cisplatin (CDDP), irinotecan, vinorelbine, or capecitabine. 1 Fluorouracil and CDDP combination therapy (FP) is regarded as standard, 2 with median survival times reported to be 9.2 months for responders and 5.3 months for non-responders. 3 The response rates reported with FP range from 35% to 40%, whereas the 2-year survival rates of patients with locally advanced EC range from 8% to 55%, with a mean of 27%. 4, 5 Preoperative chemotherapy with FP can be regarded as standard treatment for patients with stage II/III esophageal squamous cell carcinoma (ESCC). 6 Furthermore, an antitumor effect is expected with the development of a combination therapy comprising a triplet regimen, molecular targeted drug, and immunity checkpoint inhibitor. 7, 8 Efforts to achieve individualized treatment by genetic analysis have also begun in the presence of differences in histopathological type between Caucasians and Asians. Video-assisted thoracoscopic surgery (VATS) in the pursuit of minimal invasiveness and the pursuit of safe perioperative management by the medical team are widespread in the field of esophageal surgery and treatment. In the present review article, we report recent advancements in the treatment of EC.
| REN EWAL OF THE JAPANESE CLASSIFICATION OF ESOPHAGE AL CANCER
The 11th edition of the Japanese Classification of EC was published in 2017, and the criteria for the diagnosis of lesions located at the gastroesophageal junction have been jointly adopted by the Japa- In 2017, Okamoto et al carried out a retrospective study to identify the clinical parameters that predispose post-ESD patients to esophageal stricture after TA injection therapy. Endoscopic TA injection is not sufficient to prevent esophageal stricture in patients bearing mucosal defects covering more than seven-eighths of the esophageal circumference after ESD. 10 A randomized phase III trial started in Japan in 2014. The purpose of this study is to confirm the superiority of giving prophylactic oral steroid following ESD in terms of stricture-free survival over endoscopic local steroid injection for patients with superficial EC. 
| Minimally invasive surgery
Presently, the optimal surgical technique for EC remains unclear.
Dissemination of VATS has made it possible to accurately ascertain the surgical anatomy as a result of the magnification effect.
In 2017, a report was published using a nationwide Japanese database. Overall, 9584 patients with thoracic EC who underwent esophagectomy at 864 hospitals in 2011-2012 were evaluated.
Takeuchi et al carried out one-to-one matching between minimally invasive esophagectomy (MIE) and open esophagectomy (OE)
groups on the basis of estimated propensity scores for each patient. After propensity score matching, operative time was significantly longer in the MIE group (n = 3515) than in the OE group (n = 3515) (526 AE 149 vs 461 AE 156 minutes, P < .001), whereas blood loss was markedly less in the MIE group than in the OE group (442 AE 612 mL vs 608 AE 591 mL, P < .001). The population of patients who required more than 48 hours of postoperative respiratory ventilation was also significantly less in the MIE group than in the OE group (8.9% vs 10.9%, P = .006); however, the reoperation rate within 30 days was significantly higher in the MIE group than in the OE group (7.0% vs 5.3%, P = .004).
There were no significant differences between the MIE and OE groups in 30-day mortality rates (0.9% vs 1.1%) and operative mortality rates (2.5% vs 2.8%, respectively). They concluded that MIE was comparable with conventional OE in terms of short-term outcome after esophagectomy.
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A randomized phase III study, the Japan Clinical Oncology Group 
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The three most common techniques for thoracic esophagectomy are the transhiatal approach, Ivor Lewis esophagectomy (right thoracotomy and laparotomy), and the McKeown technique (right thoracotomy followed by laparotomy and neck incision with cervical anastomosis). 14 A report comparing the operative methods for ESCC was published by Li et al who investigated whether survival is improved by using the right thoracic approach (extended lymphadenectomy) versus the left thoracic approach (limited lymphadenectomy). Disease-free survival (DFS) and OS were compared between the right (n = 146) and left thoracic groups (n = 140). They concluded that compared with the left thoracic approach, the right thoracic approach was associated with increased DFS and OS in ESCC patients, particularly in those with lymph node involvement and/or R1-2 resection margins. 
| Perioperative chemotherapy or preoperative chemotherapy?
Preoperative chemotherapy with FP can be regarded as standard treatment for patients with stage II/III ESCC in Japan. 6 A study was reported that discussed whether preoperative treatment only is sufficient or whether it should also be given after surgery. Zhao 
| Neoadjuvant chemotherapy plus surgery versus CRT for stage II/III EC
Chemoradiotherapy is the standard for unresectable EC and can also be considered an option for resectable EC. 29 Nomura et al con- 
| Surgery after clinical failure of CRT
Long-term follow-up in the CROSS trial 24 confirmed the OS benefits for NCRT when added to surgery in patients with resectable esophageal or esophagogastric junctional cancer. This improvement is clinically relevant for both the SCC and adenocarcinoma subtypes.
Therefore, NCRT according to the CROSS trial followed by surgical resection should be regarded as a standard of care for patients with resectable locally advanced esophageal or esophagogastric junctional cancer in Western countries. However, two randomized trials addressing thoracic EC concluded that for SCC, definitive CRT alone leads to the same OS as induction CRT followed by surgery. 31, 32 One of these trials, FFCD 9102, randomized only fit, compliant, and operable responders to induction CRT, between continuation of CRT and surgery. In their analysis, Vincent et al reported that outcome in the patients not eligible for randomization was calculated to determine whether an attempt at surgery should be recommended. (Table 1) . 33 
| Novel strategy of chemotherapy
The JCOG9407 trial using FP showed an overall response rate of 33.3% and median OS of 6.7 months. 34 Moreover, this trial showed a response rate of 38%, similar to those reported in previous studies of metastatic disease. 6 As mentioned above, the combination of cisplatin (80 mg/m 2 on day 1) + 5-FU (800 mg/m 2 per day on days 1-5), repeated every 4 weeks (1 cycle), is the standard regimen used in Japanese clinical practice. 35 Development of the next generation of regimens to treat both distant metastasis and locally advanced cancer has already begun. Many studies have shown significant activity of taxanes in patients with locally advanced and metastatic EC. 36 Although a DCF regimen has been reported, it is often difficult to accomplish because of severe toxicity. Therefore, Tanaka et al developed a new biweekly-DCF (Bi-DCF) regimen and carried out a phase I/II study of Bi-DCF for advanced ESCC. After completion of the regimen, patients received esophagectomy. During chemotherapy, the most common grade 3 or 4 toxicity was neutropenia (31.3%). No treatment-related deaths were observed, and the incidence of operative morbidity was tolerable. Overall response rate (RR) after the chemotherapy was 90.3%. They concluded that this Bi-DCF regimen was well tolerated and highly active. 37 Tanaka et al also developed a new triplet regimen of docetaxel, nedaplatin, and S1 (DGS) for use in the outpatient setting and undertook a phase I/II study of DGS for advanced EC. After completion of chemotherapy, patients underwent esophagectomy. As with the Bi-DCF study, the most common grade 3 or 4 toxicity during chemotherapy was neutropenia (25.0%), no treatment-related deaths were observed, and the incidence of operative morbidity was tolerable. Overall RR after chemotherapy was 83.3%. This DGS regimen was well tolerated and highly active in the outpatient setting. 38 
| Esophageal adenocarcinoma

| Reports on Barrett's esophagus
In the USA and Western Europe, the predominant histological type of EC has shifted over the past four decades from ESC to EAC, as the incidence of EAC has increased 5-6-fold whereas the incidence of ESCC has remained relatively stable. 52 In Japan, SCC remains the predominant type in all EC. The ratio of SCC to adenocarcinoma is 26:1. No dramatic increase in adenocarcinoma has occurred, and the absolute incidence remains low in Japan. 53 The incidence of Barrett's esophagus (BE)-related neoplasia in Western countries has increased in the past several decades, and it also appears to be increasing even in Eastern countries. Therefore, it should also be noted in this area in the future.
The cost-effectiveness of surveillance in BE is still debated, and the use of biomarkers in screening and surveillance is still not recom-
mended. Evaluation of the potential role of the determination of the immunocomplexed form of SCC antigen (SCCA-immunoglobulin [Ig]
M) for the screening of BE and EAC was reported. Patients with SCCA-IgM levels above the cutoff had a 33-fold higher relative risk of harboring BE or EAC (P = .0001). Patients "at risk" with long or dysplastic BE had SCCA-IgM levels significantly higher than those with short non-dysplastic BE (P = .035), and patients with SCCA-IgM above the cutoff had an eightfold higher relative risk of their BE being "at risk." Thus, serum SCCA-IgM determination allows the identification of patients at risk for BE/EAC and the stratification of BE patients in subgroups with different cancer risk. sely resembles daily practice, this study is expected to contribute both to evidence on the effects of exercise in EC patients and to potential implementation strategies. 62 An examination of how we should invasively treat elderly EC patients was also reported by Vla- indicating sarcopenia as a potential biomarker for identifying patients likely to experience an inferior outcome. Moreover, sarcopenia was associated with anastomosis leakage (P = .032). 67 Nakashima et al 68 also reported that the incidence of anastomotic leakage and in-hospital death was significantly higher in the elderly sarcopenia group than in the elderly non-sarcopenia group (31.5% vs 15.2%, P = .015, 6.8% vs 0.0%, P = .037, respectively), and the OS rate in patients with sarcopenia correlated with a significantly poor prognosis in the elderly group (P < .001). Thus, it is shown that nutrition management is important. Takesue | 261 them, only one comparative study was included that compared esophageal stents to jejunostomy. This study reported no significant difference between the two groups with respect to complication rates (stents 22% vs jejunostomy 4%, P = .11) or increase in weight (stents 4.4 kg vs jejunostomy 4.2 kg, P = .59). 70 
| Biomarkers for chemo(radio)therapy
Research into predictive biomarkers of response of EC treated with chemo(radio)therapy are in progress. P53 for predicting EC response has been reported. 79 Li et al carried out a systematic review and meta-analysis to summarize and evaluate the biomarkers for predicting response to chemo(radio)therapy. Their results indicated that low expression of COX2, miR-200c, ERCC1, and TS, or high expression of CDC25B and p16 can be potential biomarkers for predicting the response of EC patients treated with chemo(radio)therapy. 
| Risk factors
Alcohol consumption is strongly associated with an increased risk of ESCC but is not associated with EAC. Smoking can cause EC, and Dong and Thrift emphasized the importance of focusing efforts on controlling the worldwide burden of EC by reducing alcohol and tobacco use. 81 Xu et al investigated the association and quantified the correlation between diabetes mellitus (DM) and EC by a metaanalysis. Their results showed a positive correlation between type 2 DM and EC risk (relative risk = 1.28, 95% CI 1.12-1.47, P < .001).
Subgroup analysis based on gender showed that male gender was an important risk factor for EC whereas female gender was not. In addition, subgroup analysis based on ethnicity showed that DM correlated significantly with EC in North American and European subjects, but no correlation was found in Asian subjects. Furthermore, DM correlated significantly with an increased risk of EAC. 82 
| CONCLUSION
Esophageal cancer remains a major public health problem worldwide.
Chemo(radio)therapy including novel molecular targeted drugs and immune checkpoint inhibitors will be a new therapeutic approach for patients with EC in the near future. Precision oncology and minimally invasive surgery might be new innovative approaches, but large randomized controlled trials will be required to establish global standards of care.
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